The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Rationale: Radiation therapy has become indispensable in cancer treatment. However, it is

associated with severe side effects. Innovation in radiation therapy has resulted in the

development of MR-guided radiation therapy (MRGRT) which allows high precision

radiotherapy under real time MR visualization. High precision MRGRT has the potential of

dose escalation and margin reduction and may potentially lead to higher cure rates and

less toxicity. MRGRT can be delivered by the MRI guided Linear Accelerator (MR-Linac)

which integrates a state-of-the-art linear accelerator, 1.5T diagnostic quality MRI and

an online adaptive workflow.

Objective: The Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study

(MOMENTUM) aims to accelerate the technical and clinical development of Anatomic and

Biologic MRGRT and facilitate the evidence-based introduction of the MR-Linac into

clinical practice. In MOMENTUM, technical and clinical data are gathered in order to

optimize software, evaluate treatment outcomes, toxicities and progression free, disease

free, and overall survival per disease site, and create a repository of anatomical and

biological MR sequences to develop new features.

Study design: A multi-institutional, international observational cohort study. Study

population: Cancer patients ≥ 18 years receiving treatment and/or imaging on an MR-Linac

machine are eligible for enrollment.

Main study parameters/endpoints: MOMENTUM will collect technical and clinical patient

data. The technical patient data is defined as data generated by (the use of) the

MR-Linac and will include data collection during scans performed during routine care as

well as research MRIs. Clinical data will be categorized into six classes: demographic,

disease characteristics, treatment classifiers, toxicity outcomes, cancer control

outcomes and PROs.